Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ONgoing Telmisartan Alone or in combination with Ramipril Global Endpoint Trial

Next Previous
Trial Profile

ONgoing Telmisartan Alone or in combination with Ramipril Global Endpoint Trial

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telmisartan (Primary) ; Ramipril
  • Indications Angina pectoris; Cardiovascular disorders; Heart failure; Hypertension; Intermittent claudication; Left ventricular hypertrophy; Myocardial infarction; Stroke; Unstable angina pectoris
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms ONTARGET
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 28 Mar 2019 Results of pooled post hoc analysis from ONTARGET/TRANSCEND studies assessing cardiovascular outcomes and achieved blood pressure published in the European Heart Journal.
  • 24 Dec 2018 Results assessing resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals from ONTARGET and TRANSCEND trials, published in the European Heart Journal.
  • 01 Feb 2013 Results published in the Journal of Hypertension.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top